scholarly journals Efficacy of lisdexamfetamine dimesylate for promoting occupational success in adolescents and young adults with attention-deficit/hyperactivity disorder.

2020 ◽  
Author(s):  
Chanelle T. Gordon ◽  
Gregory A. Fabiano ◽  
Kevin F. Hulme ◽  
Sandro M. Sodano ◽  
Michael Adragna ◽  
...  
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Young Adults ◽  
Attention Deficit ◽  
Adolescents And Young Adults ◽  
Lisdexamfetamine Dimesylate ◽  
Occupational Success ◽  
Hyperactivity Disorder

scholarly journals Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study

2018 ◽  
Vol 212 (4) ◽  
pp. 234-238 ◽  
Author(s):  
Kai-Lin Huang ◽  
Han-Ting Wei ◽  
Ju-Wei Hsu ◽  
Ya-Mei Bai ◽  
Tung-Ping Su ◽  
...  
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Young Adults ◽  
Risk Factor ◽  
Suicide Attempt ◽  
Attention Deficit ◽  
Suicide Attempts ◽  
Population Based ◽  
Hazard Ratio ◽  
Adolescents And Young Adults ◽  
Hyperactivity Disorder

BackgroundAttention-deficit hyperactivity disorder (ADHD) increases the risk of suicidal behaviours through psychiatric comorbidities; however, a significant direct association has not been observed between ADHD and suicide attempts.AimsTo evaluate the risk of suicide attempt in adolescents and young adults with ADHD.MethodUsing a nationwide, population-based insurance claims database, this longitudinal cohort study enrolled 20 574 adolescents and young adults with ADHD and 61 722 age- and gender-matched controls between 2001 and 2009. Any suicide attempt was identified from enrolment to 31 December 2011. The association between ADHD medications and the likelihood of suicide attempt was assessed.ResultsADHD was an independent risk factor for any suicide attempt (hazard ratio = 3.84, 95% CI = 3.19–4.62) and repeated suicide attempts (hazard ratio = 6.52, 95% CI = 4.46–9.53). Subgroup analyses of men, women, adolescents and young adults demonstrated the same trend. Methylphenidate or atomoxetine treatment did not increase the risk of suicide attempt or repeated suicide attempts. Long-term methylphenidate treatment was associated with a significantly decreased risk of repeated suicide attempts in men (hazard ratio = 0.46, 95% CI = 0.22–0.97).ConclusionADHD was a risk factor for suicide attempt and a stronger predictor of repeated suicide attempts, independent of comorbidities. Further investigation is warranted to explore the mechanism underlying the association between ADHD and suicidal behaviours.Declaration of interestNone.

scholarly journals Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults

2009 ◽  
Vol 194 (3) ◽  
pp. 273-277 ◽  
Author(s):  
Suzanne McCarthy ◽  
Philip Asherson ◽  
David Coghill ◽  
Chris Hollis ◽  
Macey Murray ◽  
...  
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Young Adults ◽  
Attention Deficit ◽  
General Practice Research Database ◽  
Treatment Discontinuation ◽  
Adolescents And Young Adults ◽  
Practice Research ◽  
Research Database ◽  
Hyperactivity Disorder ◽  
Age Related

BackgroundSymptoms of attention-deficit hyperactivity disorder (ADHD) are known to persist into adulthood in the majority of cases.AimsTo determine the prevalence of methylphenidate, dexamfetamine and atomoxetine prescribing and treatment discontinuation in adolescents and young adults.MethodA descriptive cohort study using the UK General Practice Research Database included patients aged 15–21 years from 1999 to 2006 with a prescription for a study drug.ResultsPrevalence of prescribing averaged across all ages increased 6.23-fold over the study period. Overall, prevalence decreased with age: in 2006, prevalence in males dropped 95% from 12.77 per 1000 in 15-year-olds to 0.64 per 1000 in 21-year-olds. A longitudinal analysis of a cohort of 44 patients aged 15 years in 1999 demonstrated that no patient received treatment after the age of 21 years.ConclusionsThe prevalence of prescribing by general practitioners to patients with ADHD drops significantly from age 15 to age 21 years. The fall in prescribing is greater than the reported age-related decrease in symptoms, raising the possibility that treatment is prematurely discontinued in some young adults in whom symptoms persist.

Sign in / Sign up

Export Citation Format

Share Document